About Us
Two decades of experience in producing pharmaceutical-grade cannabis
Bedrocan produces cannabis for medicinal use, both as active pharmaceutical ingredients (APIs) or raw material. At our EU-GMP-certified facilities in the Netherlands and Denmark, we produce different cannabis chemovars under fully standardised conditions. Each variety is genetically identical and delivers a consistent cannabinoid content across every batch.
Our cannabis API is used worldwide in:
- The development of pharmaceutical-grade cannabinoid-based formulations
- Clinical research programmes
- Patient treatment within regulated and compassionate medicinal cannabis programmes frameworks
Company History
- 1984 – Company founded by Tjalling Erkelens & Freerk Bruining; focus on controlled indoor cultivation of vegetables and herbs.
- 1990s – Development of standardised, quality-controlled cannabis seeds
- 2003 – Exclusive supplier to the Dutch Medicinal Cannabis Programme
- 2007 – International exports begin
- 2014– New Dutch A2 facility begins operation.
- 2017 – Bedrocan awarded GoodManufacturing Practise (GMP);new Dutch A5 facility opened.
- 2023 – Reacquired Toronto facility, preparing return to Canadian patients.
- 2025 – Opened EU-GMP-certified facility in Denmark (2,300 kg capacity).
Our Mission
Bedrocan applies decades of expertise to the standardised production of cannabis APIs. Operating under GMP and rigorous quality systems from cultivation to packaging, we contribute to the pharmaceutical development of cannabis-derived formulations that encourage healthcare professionals to prescribe with confidence.
Our Vision
Bedrocan seeks formal regulatory recognition of cannabis APIs to support the marketing authorisation of cannabis-based medicines. Bedrocan also contributes to the harmonisation of global quality standards for cannabis for medicinal use.
Our facilities
The Netherlands
Two facilities with a combined capacity of up to 7,500 kg per year, which have supplied the Dutch medicinal cannabis programme since 2003, as well as pharmaceutical manufacturers.
Denmark
Inaugurated in 2025, our EU-GMP-certified facility produces 2,300 kg per year, supplying distributors and pharmaceutical manufacturers worldwide.
Canada
Our Toronto facility, reacquired in 2023, marks the beginning of renewed operations to make pharmaceutical-quality medicinal cannabis available to Canadian patients.
